The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...

Pfizer (NYSE:PFE) has made significant updates to its diversity, equity, and inclusion (DEI) webpage, becoming the latest Big Pharma after GSK (NYSE:GSK) to revise DEI initiatives amid the Trump ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it revealed (PDF) that Walmsley took a 16% pay cut in 2024, it also laid out a new compensation ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of depemokimab in two indications. The proposed ...

GSK is studying a group of more than a million older adults in the UK to see if its shingles vaccine lowers the risk of dementia. The British drugs group, led by boss Emma Walmsley, is using the ...

Rise and shine, everyone, another busy day is on the way. We can tell by the parade of motor vehicles passing by the Pharmalot campus and the continuous rumble of commuter trains off in the distance.

EXCLUSIVE: One of the biggest pic packages is about to land at Disney, Deadline hears. This is the pitch for a Martin Scorsese-directed drama that would star Dwayne Johnson, Leonardo DiCaprio and ...

Multinational pharmaceutical company GSK’s commitment to invest up to $800 million in its facility near Marietta may have gone elsewhere without tax incentives approved by local officials last year.

and inactivated trivalent influenza vaccine (TIV; Fluarix™, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to ...

GlaxoSmithKline is investing in artificial intelligence (AI) with the hope of radically cutting the time and money needed to develop a drug. It has entered into an alliance with Exscientia, a new ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.